Abstract
We report a case of Lichen Sclerosus in a 73-year-old man who had been treated for epilepsy with carbamazepine. Lichen sclerosus et atrophicus (LSA), also called lichen sclerosus (LS), is a chronic inflammatory cutaneous condition characterized by white plaques with epidermal atrophy and scarring. To date no cases of LSA has been linked to carbamazepine, although in a few cases lichenoid eruptions but without sclero-atrophy have been described after exposure to this drug. Therefore, to our knowledge, this is the first report of a Lichen sclerosus et atrophicus induced by carbamazepine.
MeSH terms
-
Administration, Topical
-
Aged
-
Anticonvulsants / adverse effects*
-
Carbamazepine / adverse effects*
-
Carbamazepine / analogs & derivatives
-
Carbamazepine / therapeutic use
-
Drug Eruptions / diagnosis
-
Drug Eruptions / drug therapy
-
Drug Eruptions / etiology*
-
Drug Substitution
-
Epilepsy, Tonic-Clonic / drug therapy*
-
Humans
-
Lichen Sclerosus et Atrophicus / chemically induced*
-
Lichen Sclerosus et Atrophicus / diagnosis
-
Lichen Sclerosus et Atrophicus / drug therapy
-
Male
-
Steroids / administration & dosage
-
Treatment Outcome
Substances
-
Anticonvulsants
-
Steroids
-
oxcarbamazepine
-
Carbamazepine